Germany’s Medigene AG has raised €32.3 million in an oversubscribed private placement enabling it to expanded its ongoing clinical programme of prospective products for cancer using T cell receptor modified T cells.
The company issued 2.2 million new shares from its authorised capital on 24 May, representing approximately 10% of its outstanding share capital. The financing will increase the total number of registered shares of the company to 24,544,595.